

Innoventric Heterotopic Cross-Caval Portfolio Amir Danino

Title: The Innoventric Heterotopic Cross-Caval Portfolio Company name-Innoventric
Website <https://www.innoventric.com/> CEO- Amir Danino

Category: Medical Devices

SESSIONS • Why does cardiovascular disease remain the number ONE target for MedTech innovation?

o Executive Summary / Investment Rational Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths. Innoventric was founded in 2017. Innoventric runs a lean, highly focused operation with an experienced, professional, hands-on management team and a large team of enthusiastic KOLs.

Innoventric is developing an easy-to-use, reliable, and safe percutaneous solution for treating tricuspid regurgitation. The company has completed its EU first-in-human clinical trial and has initiated its US early-feasibility study. Innoventric is backed by leading medical device VCs, the European Investment Committee (Horizon), and the Israeli Innovation Authority.

o Core Technology What is the technology, its uniqueness, and its value proposition? Innoventric develops a heterotopic cross-caval tricuspid valve replacement specifically designed for the tricuspid valve environment. Our solution offers treatment for TR while leaving the native valve untouched. The procedure is very simple, takes less than 10 minutes to perform, and does not require Echo guidance or General anesthesia. Moreover, being agnostic to the native tricuspid valve Innoventric's solution can treat a very wide patient population, otherwise denied any surgical or transcatheter treatment.

o Product Profile/Pipeline Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships. Two decades of efforts to develop transcatheter TR solutions, and still, due to technological complexity, very few such technologies have reached the market. Currently, 4.5M patients suffer from TR in the US and EU. The majority of them are still not eligible for the current or pipeline transcatheter tricuspid valve therapies. Innoventric's cross-caval solutions offer ALL TR patients a simple, safe, and efficacious treatment option. o What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans Innoventric has completed its EU FIH clinical trial and has already initiated its US EFS. Once the EFS completes enrollment, Innoventric will take its technology to a US and EU pivotal study.